# Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Study · id `cardio:ct-nct01920711` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01920711](<https://clinicaltrials.gov/study/NCT01920711>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01920711

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4822 participants.

## Technical summary

Registry record NCT01920711. Randomized; double masking; primary purpose treatment. Start 2014-07-18 (actual); primary completion 2019-06-07 (actual). Results posted on 2020-09-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4822 participants (enrolled count; ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Started: 2014-07-18 (actual) (ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Primary completion: 2019-06-07 (actual) (ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Completion: 2019-06-07 (actual) (ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Results first posted: 2020-09-29 (ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Germany; Greece; Guatemala; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Norway; Peru; Philippines; Poland; Romania; Russia; Serbia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT01920711, source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01920711-2020-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- Acronym: PARAGON-HF
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): LCZ696
- Intervention (Drug): Valsartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (`cardio:pubmed-31475794`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (`cardio:pubmed-31806129`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF (`cardio:pubmed-31726194`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan (`cardio:pubmed-32192799`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction (`cardio:pubmed-32241619`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF (`cardio:pubmed-32731928`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction (`cardio:pubmed-32845715`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial (`cardio:pubmed-33866828`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction (`cardio:pubmed-34392331`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction (`cardio:pubmed-36050227`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction (`cardio:pubmed-38537919`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF (`cardio:pubmed-38841854`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF (`cardio:pubmed-38932589`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Analysis of the PARAGON-HF Study Results Using Win Ratio (`cardio:pubmed-39193709`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial (`cardio:pubmed-39212045`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial (`cardio:pubmed-39217577`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial (`cardio:pubmed-39570234`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial (`cardio:pubmed-40265602`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial (`cardio:pubmed-39873282`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 072d0d61d0ef63eb7943fba67129998d1b563cbc0c53ce2f4ce2b4c2ee8298ec
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
